Categories AlphaGraphs, Earnings, Health Care

Teva Pharmaceuticals (TEVA) Q2 2020 earnings: Reaffirms FY20 outlook

Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street’s revenue targets. The drug manufacturer reported adjusted EPS of $0.53 on revenue of $3.87 billion for the second quarter of 2020. Teva also confirmed its full-year 2020 outlook. TEVA stock was trading up about 3% in the pre-market trading hours.

For fiscal 2020, the company reaffirmed its previously announced outlook. Revenues are expected to be between $16.6 billion and $17 billion and EPS is forecast to be between $2.30 and $2.55 for FY20.

Teva Pharmaceuticals (TEVA) Q2 2020 Earnings Infograph

Revenues slipped 7% year-over-year due to lower revenues from generics, OTC and COPAXONE in all regions and lower revenues from QVAR and BENDEKA/TREANDA in North America segment. Also, demand reduced for certain Teva products, resulting from the impact the COVID-19 pandemic had on purchasing patterns.

[irp posts=”68053″]

“During the quarter, we experienced lower sales of our generic and OTC products in all regions. The lower generics and OTC sales in Europe and International Markets were in line with our expectations, after the unusually high demand seen in the prior quarter due to the initial response to the pandemic,” said CEO Kare Schultz.

Get more insights on what management and analysts discuss on quarterly results. Stay tuned here for Teva Q2 2020 earnings call transcript

Most Popular

Target Corp posts strong results in Q4: Infographic

Target Corporation (NYSE: TGT) reported fourth-quarter 2020 financial results before the opening bell today. The department store chain reported Q4 revenue of $28.3 billion, up 21% year-over-year and higher than

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top